company background image
BCEL

Atreca NasdaqGS:BCEL Stock Report

Last Price

US$0.97

Market Cap

US$38.1m

7D

-9.8%

1Y

-70.3%

Updated

07 Dec, 2022

Data

Company Financials +
BCEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BCEL Stock Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.

Atreca, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atreca
Historical stock prices
Current Share PriceUS$0.97
52 Week HighUS$5.36
52 Week LowUS$0.90
Beta0.58
1 Month Change-37.16%
3 Month Change-46.18%
1 Year Change-70.30%
3 Year Change-93.63%
5 Year Changen/a
Change since IPO-94.60%

Recent News & Updates

Atreca GAAP EPS of -$0.72 misses by $0.02

Aug 08

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Jun 18
Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Recent updates

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Jun 18
Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Mar 05
Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Sep 02
Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

May 14
We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Jan 29
Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Dec 07
We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Shareholder Returns

BCELUS BiotechsUS Market
7D-9.8%1.9%-0.4%
1Y-70.3%-11.2%-20.6%

Return vs Industry: BCEL underperformed the US Biotechs industry which returned -6.5% over the past year.

Return vs Market: BCEL underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is BCEL's price volatile compared to industry and market?
BCEL volatility
BCEL Average Weekly Movement10.5%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: BCEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: BCEL's weekly volatility has decreased from 33% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201091John Orwinhttps://www.atreca.com

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients.

Atreca, Inc. Fundamentals Summary

How do Atreca's earnings and revenue compare to its market cap?
BCEL fundamental statistics
Market CapUS$38.06m
Earnings (TTM)-US$105.33m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BCEL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$105.33m
Earnings-US$105.33m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.70
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BCEL perform over the long term?

See historical performance and comparison